PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.01
Negative OCF/share while CRVO has 0.00. Joel Greenblatt would question the viability of operations in comparison.
-0.01
Negative FCF/share while CRVO stands at 0.00. Joel Greenblatt would demand structural changes or cost cuts.
No Data
No Data available this quarter, please select a different quarter.
0.60
Ratio above 1.5x CRVO's 0.13. David Dodd would see if the business collects cash far more effectively.
No Data
No Data available this quarter, please select a different quarter.